AV-203

ERBB3 inhibitory antibody · AVEO Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AV-203, covering 2015-04-08 to 2015-04-08. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors [Phase 1]

See pricing